MedTrace Logo

Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure

NCT07478575 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2026-03-17

No results posted yet for this study

Summary

This retrospective cohort study investigates the effects of SGLT2 inhibitor therapy on erythropoiesis and its association with cardiac and renal outcomes in patients with chronic heart failure. The study will compare hematological parameters, echocardiographic measures, and clinical outcomes between patients who initiated SGLT2 inhibitor therapy and a matched control group receiving guideline-directed medical therapy alone over a 12-month follow-up period.

Conditions

Sponsors & Collaborators

  • Slovenian Research Agency

    collaborator OTHER

  • University Medical Centre Ljubljana

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2024-12-31
Completion
2026-12-31

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07478575 on ClinicalTrials.gov